This study revealed the molecular heterogeneity of BCs through gene expression patterns, leading to the categorization of BC into four main groups: Luminal A (50–60% of cases), Luminal B (10% of cases), HER2-positive (20% of cases), and basal-like triple-negative tumors (approximately 10% of cases). Here, ERBB2 is linked to breast cancer.